Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/the-development-of-androgen-independent-prostate-cancer-CEYB0LS649
References (105)
-
C. Vogel, M. Cobleigh, D. Tripathy, J. Gutheil, Lyndsay Harris, L. Fehrenbacher, D. Slamon, M. Murphy, W. Novotny, M. Burchmore, S. Shak, S. Stewart (2001)
First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report.European journal of cancer, 37 Suppl 1
-
F. Labrie, A. Dupont, A. Bélanger, R. St-Arnaud, M. Giguère, Y. Lacourciére, J. Emond, G. Monfette (1986)
Treatment of prostate cancer with gonadotropin-releasing hormone agonists.Endocrine reviews, 7 1
-
B. Gottlieb, B. Gottlieb, H. Lehväslaiho, L. Beitel, R. Lumbroso, L. Pinsky, M. Trifiro, M. Trifiro (1996)
The androgen receptor gene mutations databaseNucleic acids research, 24 1
-
R. Greenlee, Taylor Murray, Sherry Bolden, P. Wingo (2000)
Cancer statistics, 2000CA: A Cancer Journal for Clinicians, 50
-
Xiao-yan Zhao, B. Boyle, A. Krishnan, N. Navone, D. Peehl, D. Feldman (1999)
Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a.The Journal of urology, 162 6
-
S. Legha (1988)
Tamoxifen in the treatment of breast cancer.Annals of internal medicine, 109 3
-
MM Ittmann (1998)
Chromosome 10 alterations in prostate adenocarcinomaOncol. Rep., 5
-
L. Liotta, E. Petricoin (2000)
Molecular profiling of human cancerNature Reviews Genetics, 1
-
Y. Wen, M. Hu, K. Makino, B. Spohn, G. Bartholomeusz, D. Yan, M. Hung (2000)
HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway.Cancer research, 60 24
-
V. Stambolic, A. Suzuki, J. Pompa, G. Brothers, C. Mirtsos, Takehiko Sasaki, J. Ruland, J. Penninger, D. Siderovski, T. Mak (1998)
Negative Regulation of PKB/Akt-Dependent Cell Survival by the Tumor Suppressor PTENCell, 95
-
F. Davi, Christopher Gocke, Stephen Smith, J. Sklar (1996)
Lymphocytic progenitor cell origin and clonal evolution of human B-lineage acute lymphoblastic leukemia.Blood, 88 2
-
C. Gregory, Raymond Johnson, J. Mohler, F. French, E. Wilson (2001)
Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen.Cancer research, 61 7
-
Z Culig (1994)
Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factorCancer Res., 54
-
J. Newmark, D. Hardy, D. Tonb, B. Carter, J. Epstein, W. Isaacs, T. Brown, E. Barrack (1992)
Androgen receptor gene mutations in human prostate cancer.Proceedings of the National Academy of Sciences of the United States of America, 89 14
-
N. Craft, Y. Shostak, M. Carey, C. Sawyers (1999)
A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinaseNature Medicine, 5
-
David Agus, Howard Scher, Brian Higgins, W. Fox, Glenn Heller, Melissa Fazzari, Carlos Cordon-Cardo, David Golde (1999)
Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models.Cancer research, 59 19
-
Å. Borg, B. Baldetorp, M. Fernö, D. Killander, Hampus Olsson, S. Rydén, H. Sigurdsson (1994)
ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer.Cancer letters, 81 2
-
Xinyi Wu, K. Senechal, M. Neshat, Y. Whang, C. Sawyers (1998)
The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway.Proceedings of the National Academy of Sciences of the United States of America, 95 26
-
Wen-Hsiang Lee, Ronald Morton, J. Epstein, James Brooks, P. Campbell, G. Bova, W. Hsieh, W. Isaacs, W. Nelson (1994)
Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis.Proceedings of the National Academy of Sciences of the United States of America, 91 24
-
Xiao-yan Zhao, P. Malloy, A. Krishnan, S. Swami, N. Navone, D. Peehl, D. Feldman (2000)
Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptorNature Medicine, 6
-
D. Slamon, W. Godolphin, L. Jones, J. Holt, Steven Wong, D. Keith, W. Levin, S. Stuart, J. Udove, A. Ullrich, M. Press (1989)
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.Science, 244 4905
-
(1998)
Testbook of Endocrinology 9th edn -
M. Taplin, G. Bubley, T. Shuster, Martha Frantz, A. Spooner, G. Ogata, H. Keer, S. Balk (1995)
Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.The New England journal of medicine, 332 21
-
Jaya Gaddipati, D. Mcleod, H. Heidenberg, I. Sesterhenn, Michael Finger, J. Moul, S. Srivastava (1994)
Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers.Cancer research, 54 11
-
M. Ittmann (1998)
Chromosome 10 alterations in prostate adenocarcinoma (review).Oncology reports, 5 6
-
Marco Marcelli, M. Ittmann, Stefania Mariani, R. Sutherland, Rajni Nigam, Lata Murthy, Yali Zhao, Dino DiConcini, E. Puxeddu, Adil Esen, James Eastham, N. Weigel, Dolores Lamb (2000)
Androgen receptor mutations in prostate cancer.Cancer research, 60 4
-
O. Dalesio, H. Tinteren, M. Clarke, R. Peto, F. Schröder, I. Dechering, V. Evans, J. Godwin, B. Blumenstein, Crawford, L. Denis, Hall Rr, Catherine Hill, P. Iversen, W. Shipley, M. Soloway, R. Sylvester, Collaborat Pct. (2000)
Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trialsThe Lancet, 355
-
Z. Culig, J. Hoffmann, M. Erdel, I. Eder, A. Hobisch, A. Hittmair, G. Bartsch, G. Utermann, Martin Schneider, K. Parczyk, H. Klocker (1999)
Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model systemBritish Journal of Cancer, 81
-
R. Campbell, P. Bhat-Nakshatri, N. Patel, D. Constantinidou, S. Ali, H. Nakshatri (2001)
Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance.The Journal of biological chemistry, 276 13
-
T. McDonnell, P. Troncoso, S. Brisbay, C. Logothetis, Leland Chung, J. Hsieh, S. Tu, M. Campbell (1992)
Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer.Cancer research, 52 24
-
L. Collette, U. Studer, F. Schröder, L. Denis, R. Sylvester (2001)
Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences *The Prostate, 48
-
Alvin Liu, E. Corey, F. Bladou, P. Lange, R. Vessella (1996)
Prostatic cell lineage markers: Emergence of BCL2+ cells of human prostate cancer xenograft LuCaP 23 following castrationInternational Journal of Cancer, 65
-
Takeshi Kurita, Y. Wang, A. Donjacour, C. Zhao, J. Lydon, B. O’Malley, J. Isaacs, R. Dahiya, G. Cunha (2001)
Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive systemCell Death and Differentiation, 8
-
Jing Li, Clifford Yen, D. Liaw, K. Podsypanina, S. Bose, Steven Wang, J. Puc, C. Miliaresis, L. Rodgers, R. Mccombie, S. Bigner, B. Giovanella, M. Ittmann, B. Tycko, H. Hibshoosh, M. Wigler, R. Parsons (1997)
PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate CancerScience, 275
-
P. Alen, Frank Claessens, Erik Schoenmakers, J. Swinnen, G. Verhoeven, W. Rombauts, Ben Peeters (1999)
Interaction of the putative androgen receptor-specific coactivator ARA70/ELE1alpha with multiple steroid receptors and identification of an internally deleted ELE1beta isoform.Molecular endocrinology, 13 1
-
R. Campbell, P. Bhat-Nakshatri, N. Patel, D. Constantinidou, Simak Ali, H. Nakshatri (2001)
Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor αThe Journal of Biological Chemistry, 276
-
P. Matias, P. Donner, R. Coelho, M. Thomaz, C. Peixoto, S. Macedo, N. Otto, S. Joschko, P. Scholz, A. Wegg, S. Bäsler, M. Schäfer, U. Egner, M. Carrondo (2000)
Structural Evidence for Ligand Specificity in the Binding Domain of the Human Androgen ReceptorThe Journal of Biological Chemistry, 275
-
C. Quigley, A. Bellis, K. Marschke, M. El-Awady, E. Wilson, F. French (1995)
Androgen receptor defects: historical, clinical, and molecular perspectives.Endocrine reviews, 16 3
-
Shawn McDonald, L. Brive, D. Agus, H. Scher, K. Ely (2000)
Ligand responsiveness in human prostate cancer: structural analysis of mutant androgen receptors from LNCaP and CWR22 tumors.Cancer research, 60 9
-
S. Datta, A. Brunet, M. Greenberg (1999)
Cellular survival: a play in three Akts.Genes & development, 13 22
-
Warren Gregory (1953)
A Preliminary ReportPostgraduate Medical Journal, 29
-
J. Graff, B. Konicek, A. Mcnulty, Zejing Wang, K. Houck, Sheryl Allen, J. Paul, Ahed Hbaiu, Robin Goode, G. Sandusky, R. Vessella, B. Neubauer (2000)
Increased AKT Activity Contributes to Prostate Cancer Progression by Dramatically Accelerating Prostate Tumor Growth and Diminishing p27Kip1 Expression*The Journal of Biological Chemistry, 275
-
Osborne Ck (1998)
Tamoxifen in the Treatment of Breast CancerThe New England Journal of Medicine, 339
-
C. Palmberg, P. Koivisto, L. Kakkola, T. Tammela, O. Kallioniemi, T. Visakorpi (2000)
Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer.The Journal of urology, 164 6
-
M. Colombel, F. Symmans, Sixtina Gil, K. O'toole, D. Chopin, M. Benson, C. Olsson, S. Korsmeyer, R. Buttyan (1993)
Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers.The American journal of pathology, 143 2
-
J. Veldscholte, C. Berrevoets, C. Ris-Stalpers, G. Kuiper, G. Jenster, J. Trapman, A. Brinkmann, E. Mulder (1992)
The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogensThe Journal of Steroid Biochemistry and Molecular Biology, 41
-
Z. Culig, A. Hobisch, A. Hittmair, H. Peterziel, A. Cato, G. Bartsch, H. Klocker (1998)
Expression, structure, and function of androgen receptor in advanced prostatic carcinomaThe Prostate, 35
-
E. Small, S. Srinivas (1995)
The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancerCancer, 76
-
John Isaacs (1999)
The biology of hormone refractory prostate cancer. Why does it develop?The Urologic clinics of North America, 26 2
-
S. Yeh, Hui-Kuan Lin, Hong-Yo Kang, T. Thin, M. Lin, Chawnshang Chang (1999)
From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells.Proceedings of the National Academy of Sciences of the United States of America, 96 10
-
Binhua Zhou, M. Hu, S. Miller, Zhenming Yu, W. Xia, Shiaw-Yih Lin, M. Hung (2000)
HER-2/neu Blocks Tumor Necrosis Factor-induced Apoptosis via the Akt/NF-κB Pathway*The Journal of Biological Chemistry, 275
-
R. Lavinsky, Kristen Jepsen, T. Heinzel, J. Torchia, T. Mullen, R. Schiff, Alfonso DEL-RIO, M. Ricote, Sally Ngo, Joslin Gemsch, S. Hilsenbeck, C. Osborne, Christopher Glass, Michael Rosenfeld, David Rose (1998)
Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes.Proceedings of the National Academy of Sciences of the United States of America, 95 6
-
MJ Pilat, JM Kamradt, KJ Pienta (1998)
Hormone resistance in prostate cancerCancer Metastasis Rev., 17
-
S. Signoretti, R. Montironi, J. Manola, A. Altimari, Carmen Tam, G. Bubley, S. Balk, G. Thomas, I. Kaplan, L. Hlatky, P. Hahnfeldt, P. Kantoff, M. Loda (2000)
Her-2-neu expression and progression toward androgen independence in human prostate cancer.Journal of the National Cancer Institute, 92 23
-
M. Adachi, R. Takayanagi, A. Tomura, K. Imasaki, S. Kato, K. Goto, T. Yanase, S. Ikuyama, H. Nawata (2000)
Androgen-insensitivity syndrome as a possible coactivator disease.The New England journal of medicine, 343 12
-
N. Craft, Chloe Chhor, C. Tran, A. Belldegrun, J. Dekernion, O. Witte, Jonathan Said, R. Reiter, C. Sawyers (1999)
Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process.Cancer research, 59 19
-
M. Cher, M. Cher, G. Bova, D. Moore, E. Small, Peter Carroll, Sokhom Pin, J. Epstein, W. Isaacs, Ronald Jensen (1996)
Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping.Cancer research, 56 13
-
A. Brinkmann, L. Blok, P. Ruiter, P. Doesburg, K. Steketee, C. Berrevoets, J. Trapman (1999)
Mechanisms of androgen receptor activation and functionThe Journal of Steroid Biochemistry and Molecular Biology, 69
-
Hiroshi Miyamoto, S. Yeh, George Wilding, Chawnshang Chang, Chawnshang Chang (1998)
Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells.Proceedings of the National Academy of Sciences of the United States of America, 95 13
-
C. Huggins (1967)
Endocrine-induced regression of cancers.American journal of surgery, 136 2
-
G. Thalmann, R. Sikes, Tony Wu, A. Degeorges, Shih-Ming Chang, M. Ozen, S. Pathak, L. Chung (2000)
LNCaP progression model of human prostate cancer: Androgen‐independence and osseous metastasisThe Prostate, 44
-
W. McGuire, G. Chamness, S. Fuqua (1991)
Estrogen receptor variants in clinical breast cancer.Molecular endocrinology, 5 11
-
Guangzhou Han, B. Foster, Sandeep Mistry, Grant Buchanan, Jonathan Harris, W. Tilley, N. Greenberg (2001)
Hormone Status Selects for Spontaneous Somatic Androgen Receptor Variants That Demonstrate Specific Ligand and Cofactor Dependent Activities in Autochthonous Prostate Cancer*The Journal of Biological Chemistry, 276
-
P. Koivisto, J. Kononen, C. Palmberg, T. Tammela, E. Hyytinen, J. Isola, J. Trapman, K. Cleutjens, A. Noordzij, T. Visakorpi, O. Kallioniemi (1997)
Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer.Cancer research, 57 2
-
C. Gregory, B. He, Raymond Johnson, O. Ford, J. Mohler, F. French, E. Wilson (2001)
A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy.Cancer research, 61 11
-
E. Hyytinen, G. Thalmann, H. Zhau, R. Karhu, O. Kallioniemi, L. Chung, T. Visakorpi (1997)
Genetic changes associated with the acquisition of androgen-independent growth, tumorigenicity and metastatic potential in a prostate cancer model.British Journal of Cancer, 75
-
H Suzuki (1993)
Androgen receptor gene mutations in human prostate cancerJ. Steroid Biochem. Mol. Biol., 46
-
D. Slamon, B. Leyland-Jones, Steven Shak, Hank Fuchs, Virginia Paton, A. Bajamonde, Thomas Fleming, W. Eiermann, Janet Wolter, M. Pegram, J. Baselga, Larry Norton (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.The New England journal of medicine, 344 11
-
R. Medema, G. Kops, J. Bos, B. Burgering (2000)
AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1Nature, 404
-
Y. Furuya, S. Krajewski, J. Epstein, John Reed, J. Isaacs (1996)
Expression of bcl-2 and the progression of human and rodent prostatic cancers.Clinical cancer research : an official journal of the American Association for Cancer Research, 2 2
-
S. Anzick, J. Kononen, Robert Walker, D. Azorsa, M. Tanner, Xinxin Guan, G. Sauter, O. Kallioniemi, J. Trent, P. Meltzer (1997)
AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer.Science, 277 5328
-
Howell (1999)
DNA Microarrays for Analysis of Gene Expression.Molecular urology, 3 3
-
Grant Buchanan, N. Greenberg, H. Scher, Jonathan Harris, V. Marshall, W. Tilley (2001)
Collocation of androgen receptor gene mutations in prostate cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, 7 5
-
E. Ruijter, C. Kaa, G. Miller, D. Ruiter, F. Debruyne, J. Schalken (1999)
Molecular genetics and epidemiology of prostate carcinoma.Endocrine reviews, 20 1
-
F. Labrie, A. Bélanger, A. Dupont, V. Luu‐The, J. Simard, C. Labrie (1993)
Science behind total androgen blockade: from gene to combination therapy.Clinical and investigative medicine. Medecine clinique et experimentale, 16 6
-
L. Mendelsohn (2000)
Prostate cancer and the androgen receptor: strategies for the development of novel therapeutics.Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques, 55
-
Nicholas Bruchovsky, L. Klotz, M. Sadar, Crook Jm, D. Hoffart, L. Godwin, M. Warkentin, Gleave Martin, S. Goldenberg (2000)
Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations.Molecular urology, 4 3
-
N. McKenna, R. Lanz, B. O’Malley (1999)
Nuclear receptor coregulators: cellular and molecular biology.Endocrine reviews, 20 3
-
C Huggins (1967)
Endocrine-induced regression of cancersCancer Res., 27
-
S. Denmeade, Xiaohui Lin, J. Isaacs (1996)
Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancerThe Prostate, 28
-
M. Morris, H. Scher (2000)
Novel strategies and therapeutics for the treatment of prostate carcinomaCancer, 89
-
M. Taplin, G. Bubley, Y. Ko, E. Small, M. Upton, B. Rajeshkumar, S. Balk (1999)
Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.Cancer research, 59 11
-
Tianshu Gao, Ken Brantley, Erol Bolu, M. McPhaul (1999)
RFG (ARA70, ELE1) interacts with the human androgen receptor in a ligand-dependent fashion, but functions only weakly as a coactivator in cotransfection assays.Molecular endocrinology, 13 10
-
Z. Culig, A. Hobisch, M. Cronauer, C. Radmayr, J. Trapman, A. Hittmair, G. Bartsch, H. Klocker (1995)
Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor.European urology, 27 Suppl 2
-
Y. Özyi̇ği̇t, B. Aydinoğlu
Cellular and Molecular Biology -
Grant Buchanan, Miao Yang, Jonathan Harris, H. Nahm, Guangzhou Han, N. Moore, J. Bentel, R. Matusik, D. Horsfall, V. Marshall, N. Greenberg, W. Tilley (2001)
Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function.Molecular endocrinology, 15 1
-
Z. Estrov, M. Ouspenskaia, E. Felix, K. McClain, M. Lee, D. Harris, D. Pinkel, T. Zipf (1994)
Persistence of self-renewing leukemia cell progenitors during remission in children with B-precursor acute lymphoblastic leukemia.Leukemia, 8 1
-
L. Nazareth, N. Weigel (1996)
Activation of the Human Androgen Receptor through a Protein Kinase A Signaling Pathway*The Journal of Biological Chemistry, 271
-
S. Yeh, Chawnshang Chang (1996)
Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells.Proceedings of the National Academy of Sciences of the United States of America, 93 11
-
M. Gleave, H. Miayake, J. Goldie, C. Nelson, A. Tolcher (1999)
Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides.Urology, 54 6A Suppl
-
Z. Culig, A. Hobisch, M. Cronauer, A. Cato, A. Hittmair, C. Radmayr, J. Eberle, G. Bartsch, H. Klocker (1993)
Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone.Molecular endocrinology, 7 12
-
L. Chung (1995)
The role of stromal-epithelial interaction in normal and malignant growth.Cancer surveys, 23
-
J. Sack, K. Kish, Chihuei Wang, R. Attar, S. Kiefer, Yongmi An, Ginger Wu, J. Scheffler, M. Salvati, S. Krystek, R. Weinmann, H. Einspahr (2001)
Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosteroneProceedings of the National Academy of Sciences of the United States of America, 98
-
M. Eisenberger, Brent Blumenstein, E. Crawford, Gary Miller, David McLeod, P. Loehrer, George Wilding, Kathy Sears, D. Culkin, Ian Thompson, Anton Bueschen, Bruce Lowe (1998)
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.The New England journal of medicine, 339 15
-
T. Visakorpi, E. Hyytinen, P. Koivisto, M. Tanner, R. Keinänen, C. Palmberg, A. Palotie, T. Tammela, J. Isola, O. Kallioniemi (1995)
In vivo amplification of the androgen receptor gene and progression of human prostate cancerNature Genetics, 9
-
N. Makridakis, R. Ross, M. Pike, Lilly Chang, F. Stanczyk, L. Kolonel, C. Shi, MimiC. Yu, B. Henderson, J. Reichardt (1997)
A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase.Cancer research, 57 6
-
R. Pietras, M. Arboleda, Reese Dm, N. Wongvipat, Pegram, Lillian Ramos, C. Gorman, Parker Mg, M. Sliwkowski, D. Slamon (1995)
HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells.Oncogene, 10 12
-
W. Tilley, Grant Buchanan, Theresa Hickey, J. Bentel (1996)
Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence.Clinical cancer research : an official journal of the American Association for Cancer Research, 2 2
-
JE Griffin, JD Wilson (1998)
Williams Testbook of Endocrinology -
M Bui, RE Reiter (1998)
Stem cell genes in androgen-independent prostate cancerCancer Metastasis Rev., 17
-
G. Noël, Mazeron Jj (2001)
[Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials].Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 5 1
-
T. Maehama, J. Dixon (1999)
PTEN: a tumour suppressor that functions as a phospholipid phosphatase.Trends in cell biology, 9 4
-
N. Navone, M. Olivé, M. Ozen, R. Davis, P. Troncoso, S. Tu, D. Johnston, A. Pollack, S. Pathak, A. Eschenbach, C. Logothetis (1997)
Establishment of two human prostate cancer cell lines derived from a single bone metastasis.Clinical cancer research : an official journal of the American Association for Cancer Research, 3 12 Pt 1
-
M. Gleave, A. Tolcher, H. Miyake, C. Nelson, B. Brown, E. Beraldi, J. Goldie (1999)
Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.Clinical cancer research : an official journal of the American Association for Cancer Research, 5 10
-
Honglin Zhou, Xin‐Ming Li, J. Meinkoth, R. Pittman (2000)
Akt Regulates Cell Survival and Apoptosis at a Postmitochondrial LevelThe Journal of Cell Biology, 151
- Publisher
- Springer Journals
- Copyright
- Copyright © 2001 by Nature Publishing Group
- Subject
- Biomedicine; Biomedicine, general; Cancer Research
- ISSN
- 1474-175X
- eISSN
- 1474-1768
- DOI
- 10.1038/35094009
- Publisher site
- See Article on Publisher Site
Abstract
The normal prostate and early-stage prostate cancers depend on androgens for growth and survival, and androgen ablation therapy causes them to regress. Cancers that are not cured by surgery eventually become androgen independent, rendering anti-androgen therapy ineffective. But how does androgen independence arise? We predict that understanding the pathways that lead to the development of androgen-independent prostate cancer will pave the way to effective therapies for these, at present, untreatable cancers.
Journal
Nature Reviews Cancer – Springer Journals
Published: Oct 1, 2001